The Heroes of CRISPR: Cell
First CRISPR editing trial results assuage safety concerns
Nature Outlook: Genome editing
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response | Nature Medicine
Nature Medicine on Twitter: "#CRISPR–Cas9-induced DNA damage triggers p53 to limit the efficiency of #geneediting in immortalized human retinal pigment epithelial cells: https://t.co/Ofc8akirQF… https://t.co/jA1qViiOE7"
Controlling and enhancing CRISPR systems | Nature Chemical Biology
Highly efficient therapeutic gene editing of human hematopoietic stem cells | Nature Medicine
Frontiers | CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future | Oncology
Landmark CRISPR trial shows promise against deadly disease
CRISPR algorithm predicts how well gene editing will work - Scope
Precision CRISPR system averts hearing loss in mice - Boston Children's Discoveries
Genome editing - Wikipedia
Cornerstones of CRISPR–Cas in drug discovery and therapy | Nature Reviews Drug Discovery
The new frontier of genome engineering with CRISPR-Cas9 | Science
5 Big Mysteries about CRISPR's Origins - Scientific American
Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research: Molecular Therapy - Methods & Clinical Development
How CRISPR Is Changing Cancer Research and Treatment - National Cancer Institute
CRISPR/Cas gene therapy - Zhang - 2021 - Journal of Cellular Physiology - Wiley Online Library
Nature journal retracts controversial CRISPR paper after authors admit results may be wrong – Retraction Watch
CRISPR: Gene editing and beyond - YouTube
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population | Nature Medicine
Nature Medicine重磅文章：新型CRISPR-Cas9技术能够实现完整内源性基因的替换，成功治疗β-地贫小鼠模型-上海玮驰仪器有限公司
CRISPR-engineered T cells in patients with refractory cancer | Science
CRISPR–Cas: a tool for cancer research and therapeutics | Nature Reviews Clinical Oncology
Cornerstones of CRISPR–Cas in drug discovery and therapy | Nature Reviews Drug Discovery
PDF) Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
